NEW YORK, June 27, 2017 /PRNewswire/ --
If you want a Stock Review on CXRX, CYTK, DERM or ECYT then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com reviews the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges
On Monday, shares in Oakville, Canada headquartered Concordia International Corp. recorded a trading volume of 436,771 shares. The stock ended at $1.31, rising 0.77% from the last trading session. The Company's shares have gained 1.55% in the last one month. The stock is trading below its 50-day moving average by 2.30%. Furthermore, shares of Concordia, which owns a portfolio of branded and generic prescription products in the US and internationally, have a Relative Strength Index (RSI) of 52.53.
On June 21st, 2017, Concordia announced an update on the development of its long-term growth strategy. Further to previous communications, the Company's development of a long-term growth strategy is nearing completion. Once finalized, the Company intends to communicate its details with stakeholders in the second half of 2017. Access our complete research report on CXRX for free at:
South San Francisco, California headquartered Cytokinetics Inc.'s stock finished yesterday's session 3.81% lower at $13.90 with a total trading volume of 519,171 shares. The Company's shares have gained 9.45% over the previous three months and 14.40% on an YTD basis. The stock is trading above its 200-day moving average by 18.04%. Furthermore, shares of Cytokinetics, which focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining, have an RSI of 41.37. On June 23rd, 2017, Cytokinetics announced an oral presentation at the Cure SMA 2017 Annual SMA Conference on July 01st , 2017 at 10:00 a.m. in Orlando, Florida. Stacy Rudnicki, M.D., Director, Clinical Research and Development at Cytokinetics, will present data relating to patient baseline characteristics and the reasons for patient screen failure from the first cohort of the Phase-2 clinical trial of CK-2127107 in spinal muscular atrophy. The complimentary research report on CYTK can be downloaded at:
At the close of trading on Monday, shares in Menlo Park, California headquartered Dermira Inc. saw a drop of 3.49%, ending the day at $30.45. The stock recorded a trading volume of 607,770 shares, which was above its three months average volume of 480,980 shares. The Company's shares have advanced 9.34% in the last one month and 0.40% since the start of this year. The stock is trading 1.78% above its 50-day moving average. Moreover, shares of Dermira, which engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the US, have an RSI of 56.02.
On June 06th, 2017, Dermira announced the addition of Ian Clements, Ph.D. to the Company's leadership team as vice president, investor relations. Dr. Clements brings over 20 years of industry experience to the Company. Most recently, he led investor relations and corporate communications at Tobira Therapeutics, Inc., which was acquired by Allergan PLC. Register for free on DailyStockTracker.com and get access to the latest report on DERM at:
West Lafayette, Indiana headquartered Endocyte Inc.'s shares ended the day 1.32% higher at $1.53. A total volume of 588,057 shares was traded, which was above their three months average volume of 581,150 shares. The stock is trading 29.70% below its 50-day moving average. Additionally, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have an RSI of 34.92.
On June 02nd, 2017, Endocyte announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted (PSMA-targeted) tubulysin prostate cancer therapy. The Company will narrow the EC1169 development program to focus only on the cohort of taxane-exposed, metastatic castration-resistant prostate cancer patients, for which a top-line efficacy assessment of the expansion phase of this phase-1 trial is expected before the end of 2017.
On June 05th, 2017, research firm Wedbush downgraded the Company's stock rating from 'Outperform' to 'Neutral' while revising its previous target price from $8 a share to $2 a share. Download your free research report on ECYT at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Statins are a group of drugs which help to lower the blood cholesterol levels.
Niemann-Pick disease is a group of inherited metabolic disorders in which cholesterol and lipids ...
Raspberries are packed with important nutrients, vitamins and minerals. They help boost immunity, ...View All